Camp4 Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Camp4 Therapeutics (CAMP).

Price Target Range — 8 Quarters

Analyst Consensus — 12 Analysts

1S.Buy

10Buy

1Sell

Consensus RatingOverweight# Analysts12Avg. Consensus PT$10Upside to Avg. PT+169.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 23, 2026	Raymond James	Tiago Fauth	Initiate	Strong Buy	$10
Oct 15, 2026	Needham	Joseph Stringer	Initiate	Buy	$8
Oct 5, 2026	Oppenheimer	Kostas Biliouris	Initiate	Outperform	$15
Sep 29, 2026	Chardan Capital	Keay Nakae	PT Cut	Buy	$7→$6
Aug 14, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$12→$15
Jun 16, 2026	JP Morgan	Anupam Rama	Upgrade	Neutral→Overweight	$5→$9
Jun 10, 2026	Chardan Capital	Keay Nakae	Initiate	Buy	$7
Apr 14, 2026	Rodman & Renshaw	Seema Sheoran	Initiate	Buy	$7
Apr 2, 2026	Leerink Partners	Mani Foroohar	PT Raise	Outperform	$8→$9
Oct 2, 2025	Cantor Fitzgerald	Steve Seedhouse	Initiate	Overweight	$7
Sep 16, 2025	JP Morgan	Anupam Rama	Downgrade	Overweight→Neutral	—
Sep 15, 2025	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$18→$12
May 27, 2025	Wedbush	Yun Zhong	Initiate	Outperform	$8
Nov 5, 2024	William Blair	Myles Minter	Initiate	Outperform	—
Nov 5, 2024	Leerink Partners	Mani Foroohar	Initiate	Outperform	$17
Nov 5, 2024	JP Morgan	Eric Joseph	Initiate	Overweight	$23
Nov 5, 2024	Piper Sandler	Edward Tenthoff	Initiate	Overweight	$18
Jan 11, 2024	Goldman Sachs	Jerry Revich	PT Cut	Sell	$8→$7

Analyst Ratings News

PRO
Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10

Raymond James analyst Tiago Fauth initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8

Needham analyst Joseph Stringer initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6

Chardan Capital analyst Keay Nakae maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Buy and lowers the price target from $6.5 to $6.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.

Benzinga Newsdesk

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey. See full list here.

Avi Kapoor

This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top analysts upgraded XOM, CAMP, EXR, WPC, and KRC stocks, with price targets ranging from $44 to $154. See other analysts' views on these stocks.

Avi Kapoor

Camp4 Therapeutics Corp

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Camp4 Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10

PRO
Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8

PRO
Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6

PRO
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

People Also Watch

People Also Watch

Camp4 Therapeutics Corp

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Camp4 Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORaymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10

PRONeedham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8

PROChardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6

PROPiper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

People Also Watch

People Also Watch

PRO
Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10

PRO
Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8

PRO
Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6

PRO
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15